CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided a business update.
- and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided a business update.
- We expanded our partnership model with a joint venture in Saudi Arabia, securing a $30 million investment and additional milestone payments.
- With this progress at the forefront, CENTOGENE is positioned for growth and a path towards profitability.
- There can be no assurance that our strategic review process will result in any transaction or other strategic outcome.